The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting

Michael J. Tisdale*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Atrophy of skeletal muscle is common to a number of conditions, including cancer, sepsis, AIDS, renal failure, diabetes, severe trauma, and burns. In all cases, protein synthesis in skeletal muscle is depressed, whereas protein degradation is increased through an increase in activity and expression of the ubiquitin-proteasome proteolytic pathway. This pathway is not responsive to simple nutritional intervention. Certain agents, including glucocorticoids, cytokines, proteolysis-inducing factor (PIF), and oxidative stress, are thought to be responsible for the induction of the ubiquitin-proteasome pathway in skeletal muscle in catabolic conditions. Insulin suppresses activation of this pathway, and loss of insulin action in diabetes leads to muscle wasting. Cytokines, PIF, and reactive oxygen species (ROS) are thought to induce proteasome expression through activation of the transcription factor nuclear factor kappa B (NF-κB). Targets for therapeutic intervention include antagonists of the inducers of proteasome expression, intracellular signaling pathways leading to activation of NF-κB, and the enzymes inducing ubiquitin conjugation to the substrate protein (myosin), as well as the proteasome itself. Anticytokine and anti-PIF antibodies are effective in attenuating muscle protein degradation in certain experimental animal models, and glucocorticoid receptor antagonists are effective in the treatment of sepsis. Agents that inhibit NF-κB activation, such as resveratrol, thalidomide, ibuprofen, eicosapentaenoic acid, and β-hydroxy-β-methylbutyrate, are effective in the preservation of skeletal muscle mass in cachexia. These results suggest that the ubiquitin-proteasome pathway is an appropriate therapeutic target to prevent muscle wasting.

Original languageEnglish
Pages (from-to)209-217
Number of pages9
JournalJournal of Supportive Oncology
Volume3
Issue number3
Publication statusPublished - 1 May 2005

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Proteolysis
Muscles
NF-kappa B
Skeletal Muscle
Sepsis
Therapeutics
Insulin
Cytokines
Cachexia
Thalidomide
Eicosapentaenoic Acid
Muscle Proteins
Ibuprofen
Glucocorticoid Receptors
Myosins
Burns
Glucocorticoids
Atrophy

Cite this

@article{7ddceb28dad64db4ad6bdda61b084bc7,
title = "The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting",
abstract = "Atrophy of skeletal muscle is common to a number of conditions, including cancer, sepsis, AIDS, renal failure, diabetes, severe trauma, and burns. In all cases, protein synthesis in skeletal muscle is depressed, whereas protein degradation is increased through an increase in activity and expression of the ubiquitin-proteasome proteolytic pathway. This pathway is not responsive to simple nutritional intervention. Certain agents, including glucocorticoids, cytokines, proteolysis-inducing factor (PIF), and oxidative stress, are thought to be responsible for the induction of the ubiquitin-proteasome pathway in skeletal muscle in catabolic conditions. Insulin suppresses activation of this pathway, and loss of insulin action in diabetes leads to muscle wasting. Cytokines, PIF, and reactive oxygen species (ROS) are thought to induce proteasome expression through activation of the transcription factor nuclear factor kappa B (NF-κB). Targets for therapeutic intervention include antagonists of the inducers of proteasome expression, intracellular signaling pathways leading to activation of NF-κB, and the enzymes inducing ubiquitin conjugation to the substrate protein (myosin), as well as the proteasome itself. Anticytokine and anti-PIF antibodies are effective in attenuating muscle protein degradation in certain experimental animal models, and glucocorticoid receptor antagonists are effective in the treatment of sepsis. Agents that inhibit NF-κB activation, such as resveratrol, thalidomide, ibuprofen, eicosapentaenoic acid, and β-hydroxy-β-methylbutyrate, are effective in the preservation of skeletal muscle mass in cachexia. These results suggest that the ubiquitin-proteasome pathway is an appropriate therapeutic target to prevent muscle wasting.",
author = "Tisdale, {Michael J.}",
year = "2005",
month = "5",
day = "1",
language = "English",
volume = "3",
pages = "209--217",
journal = "Journal of Supportive Oncology",
issn = "1544-6794",
publisher = "Biolink Communications, Inc.",
number = "3",

}

The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting. / Tisdale, Michael J.

In: Journal of Supportive Oncology, Vol. 3, No. 3, 01.05.2005, p. 209-217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting

AU - Tisdale, Michael J.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Atrophy of skeletal muscle is common to a number of conditions, including cancer, sepsis, AIDS, renal failure, diabetes, severe trauma, and burns. In all cases, protein synthesis in skeletal muscle is depressed, whereas protein degradation is increased through an increase in activity and expression of the ubiquitin-proteasome proteolytic pathway. This pathway is not responsive to simple nutritional intervention. Certain agents, including glucocorticoids, cytokines, proteolysis-inducing factor (PIF), and oxidative stress, are thought to be responsible for the induction of the ubiquitin-proteasome pathway in skeletal muscle in catabolic conditions. Insulin suppresses activation of this pathway, and loss of insulin action in diabetes leads to muscle wasting. Cytokines, PIF, and reactive oxygen species (ROS) are thought to induce proteasome expression through activation of the transcription factor nuclear factor kappa B (NF-κB). Targets for therapeutic intervention include antagonists of the inducers of proteasome expression, intracellular signaling pathways leading to activation of NF-κB, and the enzymes inducing ubiquitin conjugation to the substrate protein (myosin), as well as the proteasome itself. Anticytokine and anti-PIF antibodies are effective in attenuating muscle protein degradation in certain experimental animal models, and glucocorticoid receptor antagonists are effective in the treatment of sepsis. Agents that inhibit NF-κB activation, such as resveratrol, thalidomide, ibuprofen, eicosapentaenoic acid, and β-hydroxy-β-methylbutyrate, are effective in the preservation of skeletal muscle mass in cachexia. These results suggest that the ubiquitin-proteasome pathway is an appropriate therapeutic target to prevent muscle wasting.

AB - Atrophy of skeletal muscle is common to a number of conditions, including cancer, sepsis, AIDS, renal failure, diabetes, severe trauma, and burns. In all cases, protein synthesis in skeletal muscle is depressed, whereas protein degradation is increased through an increase in activity and expression of the ubiquitin-proteasome proteolytic pathway. This pathway is not responsive to simple nutritional intervention. Certain agents, including glucocorticoids, cytokines, proteolysis-inducing factor (PIF), and oxidative stress, are thought to be responsible for the induction of the ubiquitin-proteasome pathway in skeletal muscle in catabolic conditions. Insulin suppresses activation of this pathway, and loss of insulin action in diabetes leads to muscle wasting. Cytokines, PIF, and reactive oxygen species (ROS) are thought to induce proteasome expression through activation of the transcription factor nuclear factor kappa B (NF-κB). Targets for therapeutic intervention include antagonists of the inducers of proteasome expression, intracellular signaling pathways leading to activation of NF-κB, and the enzymes inducing ubiquitin conjugation to the substrate protein (myosin), as well as the proteasome itself. Anticytokine and anti-PIF antibodies are effective in attenuating muscle protein degradation in certain experimental animal models, and glucocorticoid receptor antagonists are effective in the treatment of sepsis. Agents that inhibit NF-κB activation, such as resveratrol, thalidomide, ibuprofen, eicosapentaenoic acid, and β-hydroxy-β-methylbutyrate, are effective in the preservation of skeletal muscle mass in cachexia. These results suggest that the ubiquitin-proteasome pathway is an appropriate therapeutic target to prevent muscle wasting.

UR - http://www.scopus.com/inward/record.url?scp=20744447058&partnerID=8YFLogxK

M3 - Article

C2 - 15915823

AN - SCOPUS:20744447058

VL - 3

SP - 209

EP - 217

JO - Journal of Supportive Oncology

JF - Journal of Supportive Oncology

SN - 1544-6794

IS - 3

ER -